Summary: Merck & Co., Inc.

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company has a good ESG score relative to its sector, according to MSCI.

Highlights: Merck & Co., Inc.

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • With a P/E ratio at 12.35 for the current year and 10.38 for next year, earnings multiples are highly attractive compared with competitors.
  • The company has a low valuation given the cash flows generated by its activity.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses: Merck & Co., Inc.

  • With an enterprise value anticipated at 3.77 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings Chart: Merck & Co., Inc.

Source: Surperformance

ESG chart: Merck & Co., Inc.

Source: MSCI

Add to a list
Fundamentals Valuation Revisions of Fundamental Estimates Capi.($)
219B
779B
376B
370B
339B
254B
224B
212B
159B
145B
Average 307.62B
Weighted average by Cap.
See all sector ratings
Investor
Trader
ESG MSCI
A

Financials

Sales growth
EPS Growth
Profitability
Net margin
Financial Health

Valuation

P/E ratio
EV/REVENUE
EV/EBITDA
PBR
Yield

Revisions

1 year Revenue revision
4 months Revenue revision
1 months Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analysts' recommendations
4m Revision of opinion
Potential Price Target
4m Target Price Revision
12m Target Price Revision

Business Predictability

Earnings quality
Analyst Coverag
Divergence of analysts' recommendations
Divergence of Target Price
Divergence of analysts' opinions

ESG

Environment
Social
Governance
Controversy
ESG: Ethical controversies
ESG: Human rights controversies
ESG: Tax subsidies controversies
Sharia compliant

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. MRK Stock
  4. Ratings Merck & Co., Inc.